ArticleInternational journal of clinical and experimental medicine2015
In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Transposon-sequencing across multiplemBio · 2025Article
- First isolation of Mycobacterium brisbanense from humans in the Americas.Memorias do Instituto Oswaldo Cruz · 2025Article
- Dual Infection of an Open Fracture Caused byAntibiotics (Basel, Switzerland) · 2022Article
- High Rates of Antimicrobial Resistance in Rapidly Growing Mycobacterial Infections in Taiwan.Pathogens (Basel, Switzerland) · 2022Article
- Transposon mutagenesis ineLife · 2022Article
- Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.Antimicrobial agents and chemotherapy · 2022Article
- Mycobacterium abscessus drug discovery using machine learning.Tuberculosis (Edinburgh, Scotland) · 2022Article
- TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2020Article
- Mycobacterial Response to Organic Solvents and Possible Implications on Cross-Resistance With Antimicrobial Agents.Frontiers in microbiology · 2018Article
- Rifabutin Is Active against Mycobacterium abscessus Complex.Antimicrobial agents and chemotherapy · 2017Article
- Draft Genome Sequence ofGenome announcements · 2017Article
- Drug Susceptibility of 33 Reference Strains of Slowly Growing Mycobacteria to 19 Antimicrobial Agents.BioMed research international · 2017Article
- Treatment of Non-Tuberculous Mycobacterial Lung Disease.Current treatment options in infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapidly growing mycobacteria (RGM) are human pathogens that are relatively easily identified by acid-fast staining but are proving difficult to treat in the clinic. In this study, we performed susceptibility testing of 40 international reference RGM species against 20 antimicrobial agents using the cation-adjusted Mueller-Hinton (CAMH) broth microdilution based on the minimum inhibitory concentration (MIC) assay recommended by the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The results demonstrated that RGM organisms were resistant to the majority of first-line antituberculous agents but not to second-line fluoroquinolones or aminoglycosides. Three drugs (amikacin, tigecycline and linezolid) displayed potent antimycobacterial activity against all tested strains. Capreomycin, levofloxacin and moxifloxacin emerged as promising candidates for the treatment of RGM infections, and cefoxitin and meropenem were active against most strains. Mycobacterium chelonae (M. chelonae), M. abscessus, M. bolletii, M. fortuitum, M. boenickei, M. conceptionense, M. pseudoshottsii, M. septicum and M. setense were the most resistant RGM species. These results provide significant insight into the treatment of RGM species and will assist optimization of clinical criteria.
Indexed as
Identifiers
26629031PMC4658920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.